Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis
Phase 2
Withdrawn
- Conditions
- Ocular ItchingOcular AllergySeasonal Allergic ConjunctivitisPerennial Allergic ConjunctivitisConjunctivitis, Allergic
- Interventions
- Drug: PRO-118 Ophthalmic Solution 0.020 %Drug: PRO-118 Ophthalmic Solution 0.015%Drug: PRO-118 Ophthalmic Solution 0.015 %Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2012-03-01
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Registration Number
- NCT01541904
- Locations
- 🇲🇽
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico
🇲🇽"Instituto de Oftalmología Fundación Conde de Valenciana, I.A.P, Mexico City, Mexico
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 35
- Registration Number
- NCT01535443
- Locations
- 🇲🇽
Unidad Medica "Grupo Pediátrico", Guadalajara, Jalisco, Mexico
Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide
Phase 2
Completed
- Conditions
- Primary Open Angle GlaucomaOcular Hypertension
- Interventions
- Drug: dorzolamide-timolol-brimonidine
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 124
- Registration Number
- NCT01062971
- Locations
- 🇲🇽
Instituto de la Visión. Hospital Universitario La Carlota. Universidad de Montemorelos, Montemorelos, Nuevo Leon, Mexico
© Copyright 2025. All Rights Reserved by MedPath